Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Type 2 diabetes (T2D) and Clear-cell renal cell carcinoma (ccRCC) are both complicated diseases which incidence rates gradually increasing. Population based studies show that severity of ccRCC might be associated with T2D. However, so far, no researcher yet investigated about the molecular ...
The association between body mass index (BMI) and mortality among individuals with renal cell cancer (RCC) is debated, with some observational studies suggesting a lower mortality associated with higher BMI. However, methodological issues such as confounding and reverse causation may bias ...
In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the goals of a study evaluating camu camu with ipilimumab and nivolumab for treating metastatic renal cell carcinoma.
Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.
Neil J. Shah, MBBS, discusses treatment patterns and clinical outcomes in metastatic renal cell carcinoma after an immuno-oncology/TKI combination.
David A. Braun, MD, PhD, discusses the variety of therapies available for the treatment of patients with kidney cancer.
Higher peak doses of corticosteroids for immune-related adverse events are associated with worse outcomes across tumor types among patients receiving ICIs.
Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.
Soki Kashima, MD, PhD, discusses a study investigating T-cell phenotypes associated with response or resistance to checkpoint inhibitors in RCC.
“The challenge now is to understand how these key aspects of mitochondrial metabolism become activated, why they stimulate metastasis, and whether we can safely block them,” says Ralph J. DeBerardinis, MD, PhD.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.